+

REQUEST AN ABBOTT REP

Contact now
TAVI

NAVITOR™ TAVI

The Index Valve

TAVI

NAVITOR™ TAVI

The Index Valve

Navitor is the Index Valve engineered for more than today’s procedure.

Navitor TAVI preserves options, sustains hemodynamics and delivers predictably—supporting both the immediate and long-term needs of your patients.

Navitor TAVI offers a lifesaving treatment option for individuals with symptomatic severe aortic stenosis who are at high or greater risk for traditional open-heart surgery. This includes patients with considerations related to age, frailty, or other health conditions, making TAVI a viable and less invasive option.

Watch to see how Editha benefitted from TAVI therapy

Editha was experiencing challenges associated with aortic stenosis that impacted her life. Her heart team treated her with Navitor TAVI for the predictable delivery, sustained hemodynamics, and preserved future treatment options.

Attention to every detail

The Navitor Valve is engineered with meticulous attention to detail, ensuring optimal outcomes for TAVI procedures.

0%
 

MODERATE OR SEVERE PVL

1.9%
 

ALL-CAUSE
MORTALITY

1.9%
 

DISABLING
STROKE

4.2%
 

MAJOR VASCULAR
COMPLICATIONS

7.4
mm Hg

MEAN
GRADIENT

Get the valve where you need it — safely

Navitor™ is designed for safe navigation to the annulus — even through angulated anatomies and horizontal aortas — with precise implantation and full control throughout deployment supported by
the FlexNav Delivery system

*Valve may be re-sheathed and repositioned up to two times prior to full deployment.

Connect with your local representative today

Request a Rep

Find a Navitor TAVI Certified
Physician Near Me

Use this tool to refer a patient or consult with a certified implanting physician near you.

Show nearest:
Filter by:

See the latest clinical data for Navitor

Clinical Data

MAT-2621943 v8.0 | Item approved for U.S. use only.

References
  1. Kemp C. Five-Year Outcomes of Self-expanding Intra-annular Transcatheter Heart Valve in Patients with Severe Aortic Stenosis–An Update from the Navitor IDE Study. Presented at TCT 2026, October 31- November 3, 2026.  San Diego, USA.
  2. Sathananthan, J, Hensey, M, Landes, U. et al. Long-Term Durability of Transcatheter Heart Valves: Insights From Bench Testing to 25 Years. J Am Coll Cardiol Intv. 2020 Jan, 13 (2) 235–249. https://doi.org/10.1016/j.jcin.2019.07.049
  3. Reardon M, Chehab B, Smith D, et al. 30-Day CLinical Outcomes of a Self-Expanding Transcatheter Aortic Valve: The International PORTICO NG Study. J Am Cardiol Intv. 2023 Mar, 16(6) 681-689. doi.org/10.1016/j.jcin.2023.02.002.
Important Safety Information

Rx Only

NAVITOR™ TRANSCATHETER AORTIC VALVE IMPLANTATION SYSTEM

INDICATIONS

The Navitor™ Transcatheter Aortic Valve Implantation System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).

CONTRAINDICATIONS  

The valve is contraindicated for patients with inability to tolerate antiplatelet/anticoagulant therapy or nitinol alloy (nickel and titanium), or who have active infections, including endocarditis.

POTENTIAL ADVERSE EVENTS  

Adverse events potentially associated with the use of transcatheter bioprosthetic heart valves include but are not limited to: access site complications (e.g., pain, bleeding, infection, hematoma, pseudoaneurysm, etc.); acute coronary obstruction; acute myocardial infarction; allergic reaction to antiplatelet agents, contrast medium, or valve components; aortic rupture; ascending aorta trauma; atrio-ventricular node block; cardiac arrhythmias; conduction system injury; conversion to open surgical procedure; death; dissection; embolism; emergent balloon valvuloplasty; emergent percutaneous coronary intervention (PCI); emergent surgery (i.e., coronary artery bypass, heart valve replacement); endocarditis; explantation; heart failure; hemodynamic compromise; hemolysis; hemolytic anemia; hemorrhage; hypotension or hypertension; infection; myocardial ischemia; mitral valve insufficiency; multi-organ failure; non-structural dysfunction (i.e., entrapment by pannus, paravalvular leak, inappropriate sizing or positioning); pannus; pericardial effusion; perforation of the myocardium, ventricle, or a blood vessel; permanent disability; permanent pacemaker; regurgitation; renal insufficiency or renal failure; reoperation; respiratory failure; sepsis; stroke; structural deterioration (i.e., calcification, leaflet tear); thrombosis; tamponade; transfusion; valve embolization or migration; vessel dissection or spasm.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+